Saturday 17 October 2026
Export INGN’s income statement to Excel — free account
Inogen, Inc
INGN Healthcare Medical Devices
Inogen, Inc’s revenue for fiscal 2025 (year ended December 2025) was $348.7 million, up 3.86% from fiscal 2024. In the quarter to June 2026, revenue grew 3.04%, EPS grew 6.67% and free cash flow fell 51.2%, each against the same quarter a year earlier.
6.25
0.05
−0.79%
Follow INGN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.64 | 0.51 | 0.48 | 0.49 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
102.08 | (189.57) | (25.26) | 59.21 | |
P/B ratio |
1.12 | 0.93 | 0.92 | 1.00 | |
Price to Tangible BV |
1.43 | 1.19 | 1.18 | 1.27 | |
EV/Sales |
0.28 | 0.17 | 0.16 | 0.19 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.29) | (5.18) | (51.80) | (26.94) | |
EV/FCF |
(5.04) | (3.27) | (7.58) | (8.62) | |
Quick Ratio |
2.54 | 2.51 | 2.50 | 2.16 | |
Current Ratio |
3.14 | 3.12 | 3.10 | 2.74 | |
Net Debt/EBITDA |
65.63 | 28.30 | 25.15 | 267.77 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.13 | 1.17 | 1.18 | 1.19 | |
Operating CF/Net income |
(0.41) | 0.13 | 0.80 | (0.77) | |
Capex/Depreciation |
(0.30) | (0.19) | (0.04) | (0.35) | |
Research and Development Expense of Revenue |
5.24% | 6.51% | 5.99% | 6.17% | |
Selling, General and Administrative Expense of Revenue |
47.18% | 48.00% | 49.47% | 44.69% | |
Intangible Assets out of Total Assets |
0.14 | 0.14 | 0.14 | 0.13 | |
Share Based Compensation of Revenue |
1.91% | 2.22% | 2.29% | 1.86% | |
Graham Net Nets |
0.42 | 0.51 | 0.52 | 0.48 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(12.36%) | (12.80%) | (14.72%) | (13.95%) | |
Free Cash Flow Yield |
(8.68%) | (9.95%) | (4.50%) | (4.50%) | |
Revenue per Share |
3.41 | 3.07 | 3.12 | 3.52 | |
Operating CF per Share |
0.08 | (0.04) | (0.24) | 0.11 | |
Capex per Share |
(0.06) | (0.04) | (0.01) | (0.06) | |
Free Cash Flow per Share |
0.02 | (0.07) | (0.25) | 0.05 | |
Cash per Share |
4.60 | 4.54 | 4.08 | 3.95 | |
Shareholders Equity per Share |
7.28 | 7.23 | 6.69 | 6.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.28 | 7.23 | 6.69 | 6.47 | |
Free Cash Flow |
0.62 | (1.92) | (6.89) | 1.31 | |
Working Capital |
138.77 | 134.76 | 129.22 | 123.27 | |
Capital Expenditures |
(1.54) | (0.98) | (0.21) | (1.63) | |
Net Current Asset Value |
93.88 | 91.91 | 87.65 | 83.43 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.00 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
37.79 | 34.21 | 39.25 | 42.37 | |
Average Payables |
30.62 | 30.55 | 34.31 | 37.41 | |
Average Inventory |
24.20 | 25.39 | 25.63 | 26.47 | |
Average Assets |
306.59 | 297.41 | 297.17 | 298.81 | |
Average Common Equity |
191.29 | 183.05 | 190.43 | 187.18 |
Columns are period end dates